{"id":103,"date":"2022-07-02T18:16:14","date_gmt":"2022-07-02T18:16:14","guid":{"rendered":"https:\/\/staging.newportlabs.com\/?page_id=103"},"modified":"2022-07-02T18:16:15","modified_gmt":"2022-07-02T18:16:15","slug":"published-research","status":"publish","type":"page","link":"https:\/\/staging.newportlabs.com\/index.php\/about\/published-research\/","title":{"rendered":"PUBLISHED RESEARCH"},"content":{"rendered":"<!--themify_builder_content-->\n<div id=\"themify_builder_content-103\" data-postid=\"103\" class=\"themify_builder_content themify_builder_content-103 themify_builder tf_clear\">\n    \t<!-- module_row -->\n\t<div  data-lazy=\"1\" class=\"module_row themify_builder_row fullcover tb_pc3x262 tb_first tf_clearfix\" >\n\t    <div class=\"builder_row_cover tf_abs\"><\/div>\t\t<div class=\"row_inner col_align_top col-count-1 tf_box tf_w tf_rel\"  data-basecol=\"1\" data-col_tablet=\"column-full\" data-col_tablet_landscape=\"column-full\" data-col_mobile=\"column-full\">\n\t\t\t<div  data-lazy=\"1\" class=\"module_column tb-column col-full first tb_lpri263 tf_box\">\n\t\t\t    \t        <div class=\"tb-column-inner tf_box tf_w\">\n\t\t    <!-- module text -->\n<div  class=\"module module-text tb_bx52264   \" data-lazy=\"1\">\n        <div  class=\"tb_text_wrap\">\n    <h1>Published Research<\/h1>    <\/div>\n<\/div>\n<!-- \/module text -->\t        <\/div>\n\t    \t<\/div>\n\t\t    <\/div>\n\t    <!-- \/row_inner -->\n\t<\/div>\n\t<!-- \/module_row -->\n\t\t<!-- module_row -->\n\t<div  data-anchor=\"about\" data-hide-anchor=\"1\" data-css_id=\"toru262\" data-lazy=\"1\" class=\"module_row themify_builder_row repeat fullwidth_row_container tb_has_section tb_section-about tb_toru262 tf_clearfix hide-desktop hide-tablet hide-tablet_landscape hide-mobile\" >\n\t    \t\t<div class=\"row_inner col_align_top col-count-2 tf_box tf_w tf_rel\"  data-basecol=\"2\" data-col_tablet=\"column-full\">\n\t\t\t<div  data-lazy=\"1\" class=\"module_column tb-column col4-2 first tb_le80265 tf_box\">\n\t\t\t    \t        <div class=\"tb-column-inner tf_box tf_w\">\n\t\t    <!-- module text -->\n<div  class=\"module module-text tb_oxoo265    wow\" data-tf-animation=\"fadeIn\" data-lazy=\"1\">\n        <div  class=\"tb_text_wrap\">\n    <h2 style=\"text-align: center;\">About Our Custom Vaccines<\/h2>    <\/div>\n<\/div>\n<!-- \/module text -->\t        <\/div>\n\t    \t<\/div>\n\t\t<div  data-lazy=\"1\" class=\"module_column tb-column col4-2 last tb_2x1n266 repeat tf_box\">\n\t\t\t    \t        <div class=\"tb-column-inner tf_box tf_w\">\n\t\t    <!-- module text -->\n<div  class=\"module module-text tb_u61m266    wow\" data-tf-animation=\"fadeIn\" data-lazy=\"1\">\n        <div  class=\"tb_text_wrap\">\n    <p>Custom Made Vaccines have been used for many years to help address livestock diseases. Newport Laboratories has applied 21st century technology to the traditional autogenous approach to produce high quality biologics for the livestock industry. These products are formulated and produced to pinpoint the specific disease problems in your livestock. Our dedicated employees, quality products, innovative solutions and personalized customer service, are the catalyst for Newport Laboratories&#8217; success. Today, we provide Custom Made Vaccines for customers across the country.<\/p>\n<p>We invite you to look through this section of our website, and contact us to discuss how Newport Laboratories can become your partner in improving and maintaining the health of your livestock. Custom Made Vaccines are sold exclusively through practicing veterinarians. For more information about Custom Made Vaccines, contact Newport Laboratories at 800-220-2522 or contact us.<\/p>    <\/div>\n<\/div>\n<!-- \/module text -->\t        <\/div>\n\t    \t<\/div>\n\t\t    <\/div>\n\t    <!-- \/row_inner -->\n\t<\/div>\n\t<!-- \/module_row -->\n\t\t<!-- module_row -->\n\t<div  data-anchor=\"bovine\" data-hide-anchor=\"1\" data-lazy=\"1\" class=\"module_row themify_builder_row builder-parallax-scrolling tb_has_section tb_section-bovine tb_lg9v262 tf_clearfix\" >\n\t    \t\t<div class=\"row_inner col_align_top gutter-narrow col-count-1 tf_box tf_w tf_rel\">\n\t\t\t<div  data-lazy=\"1\" class=\"module_column tb-column col-full first tb_kqsl266 fullcover tf_box\">\n\t\t\t    \t        <div class=\"tb-column-inner tf_box tf_w\">\n\t\t    <!-- module accordion -->\n<div  class=\"module module-accordion tb_6ydl266 \" data-behavior=\"accordion\" data-lazy=\"1\">\n    \n    <ul class=\"ui module-accordion separate  tb_default_color\">\n\t\t    <li>\n\t\t\t<div class=\"accordion-title tf_rel\">\n\t\t\t\t<a href=\"#acc-6ydl266-0\" aria-controls=\"acc-6ydl266-0-content\" aria-expanded=\"false\">\n\t\t\t\t\t<i class=\"accordion-icon\"><svg  aria-hidden=\"true\" class=\"tf_fa tf-ti-plus\"><use href=\"#tf-ti-plus\"><\/use><\/svg><\/i>\t\t\t\t\t<i class=\"accordion-active-icon tf_hide\"><svg  aria-hidden=\"true\" class=\"tf_fa tf-ti-minus\"><use href=\"#tf-ti-minus\"><\/use><\/svg><\/i>\t\t\t\t\t<span class=\"tb_title_accordion tf_w\">Antigenic catergorization of contemporary H3N2 Swine Influenza Virus isolates using a high-throughput serum neutralization assay<\/span>\n\t\t\t\t<\/a>\n\t\t\t<\/div><!-- .accordion-title -->\n\n\t\t\t<div id=\"acc-6ydl266-0-content\" data-id=\"acc-6ydl266-0\" aria-hidden=\"true\" class=\"accordion-content tf_hide\">\n\n\t\t\t\t\t\t\t\t\t<div\t\t\t\t\t\tclass=\"tb_text_wrap\"\n\t\t\t\t\t\t>\n\t\t\t\t\t\t<p>Ben M. Hause,1 Tracy A. Oleson, Russell F. Bey,<br>Douglas L. Stine, Randy R. Simonson<\/p>\n<p><strong>Abstract<\/strong><\/p>\n<p>In vivo, neutralizing antibodies are critical for viral clearance. A high-throughput serum neutralization (HTSN) assay was developed to antigenically categorize Swine influenza virus (SIV) isolates. Uncategorized viruses were tested using a panel of antisera representing the H3N2 SIV subtypes and the results expressed as a serum neutralization ratio. Antisera were generated against contemporary isolates representing circulating H3N2 SIV subtypes (clusters I, III, IV). Reference viruses and the corresponding antisera were evaluated using traditional hemagglutination inhibition (HI) and the HTSN assays and good correlation (r 5 0.84) was observed between the 2 tests. Categorical clustering of 40 recent (2008\u20132009) SIV isolates was assessed using the HTSN assay. The H3N2 SIV isolates with amino acid similarity. 97% to the commonly used H3N2 cluster IV reference strain A\/Swine\/Ontario\/33853\/2005 (ON05) showed strong reactivity with cluster IV antisera. Isolates with, 97% amino acid similarity to ON05 sporadically or completely failed to react with any antiserum. A cluster of 3 isolates with weak reaction with cluster III antiserum may be a potential emerging cluster of H3N2 with moderate genetic similarity to cluster II H3N2 (93% similarity). Potential uses of the HTSN assay include identification of broadly cross-reactive or antigenically distinct SIV isolates for use in vaccine virus selection or as part of surveillance efforts monitoring antigenic drift.<\/p>\n<p><strong>Download Article: <a href=\"https:\/\/streamllc.com\/newport\/wp-content\/uploads\/2022\/06\/1-NL-Analysis-of-SIV-Serum-Neutralization-1_0.pdf\" target=\"_blank\" rel=\"noopener\">Click here<\/a><\/strong><\/p>\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t<\/div><!-- .accordion-content -->\n\t    <\/li>\n\t\t    <li>\n\t\t\t<div class=\"accordion-title tf_rel\">\n\t\t\t\t<a href=\"#acc-6ydl266-1\" aria-controls=\"acc-6ydl266-1-content\" aria-expanded=\"false\">\n\t\t\t\t\t<i class=\"accordion-icon\"><svg  aria-hidden=\"true\" class=\"tf_fa tf-ti-plus\"><use href=\"#tf-ti-plus\"><\/use><\/svg><\/i>\t\t\t\t\t<i class=\"accordion-active-icon tf_hide\"><svg  aria-hidden=\"true\" class=\"tf_fa tf-ti-minus\"><use href=\"#tf-ti-minus\"><\/use><\/svg><\/i>\t\t\t\t\t<span class=\"tb_title_accordion tf_w\">Genetic and antigenic characterization of recent human-like H1 (d-cluster) Swine Influenza Virus isolates<\/span>\n\t\t\t\t<\/a>\n\t\t\t<\/div><!-- .accordion-title -->\n\n\t\t\t<div id=\"acc-6ydl266-1-content\" data-id=\"acc-6ydl266-1\" aria-hidden=\"true\" class=\"accordion-content tf_hide\">\n\n\t\t\t\t\t\t\t\t\t<div\t\t\t\t\t\tclass=\"tb_text_wrap\"\n\t\t\t\t\t\t>\n\t\t\t\t\t\t<p>Genetic and antigenic characterization of recent human-like H1 (d-cluster) Swine Influenza Virus isolates<br>Ben M. Hause, MS; Tracy A. Oleson, MS;\u2028Douglas L. Stine, DVM, PhD; Russell F. Bey,\u2028PhD; Randy R. Simonson, PhD<\/p>\n<p>To assess genetic and antigenic properties of contemporary human-like H1 (d-cluster) swine influenza virus (SIV) isolates circulating in US swine herds. (As published in the Journal of Swine Health &amp; Production)<\/p>\n<p><strong>Download Article: <a href=\"https:\/\/streamllc.com\/newport\/wp-content\/uploads\/2022\/06\/2-NL-Genetic-Antigenic-Characterization-of-H1-delta-cluster-SIV-2_0.pdf\" target=\"_blank\" rel=\"noopener\">Click here<\/a><\/strong><\/p>\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t<\/div><!-- .accordion-content -->\n\t    <\/li>\n\t\t    <li>\n\t\t\t<div class=\"accordion-title tf_rel\">\n\t\t\t\t<a href=\"#acc-6ydl266-2\" aria-controls=\"acc-6ydl266-2-content\" aria-expanded=\"false\">\n\t\t\t\t\t<i class=\"accordion-icon\"><svg  aria-hidden=\"true\" class=\"tf_fa tf-ti-plus\"><use href=\"#tf-ti-plus\"><\/use><\/svg><\/i>\t\t\t\t\t<i class=\"accordion-active-icon tf_hide\"><svg  aria-hidden=\"true\" class=\"tf_fa tf-ti-minus\"><use href=\"#tf-ti-minus\"><\/use><\/svg><\/i>\t\t\t\t\t<span class=\"tb_title_accordion tf_w\">Multiple Reassortment between Pandemic (H1N1) 2009 and Endemic Influenza Viruses in Pigs, United States<\/span>\n\t\t\t\t<\/a>\n\t\t\t<\/div><!-- .accordion-title -->\n\n\t\t\t<div id=\"acc-6ydl266-2-content\" data-id=\"acc-6ydl266-2\" aria-hidden=\"true\" class=\"accordion-content tf_hide\">\n\n\t\t\t\t\t\t\t\t\t<div\t\t\t\t\t\tclass=\"tb_text_wrap\"\n\t\t\t\t\t\t>\n\t\t\t\t\t\t<p>Mariette F. Ducatez, Ben Hause, Evelyn Stigger-Rosser, Daniel Darnell, Cesar Corzo, Kevin Juleen, \u2028Randy Simonson, Christy Brockwell-Staats, Adam Rubrum, David Wang, Ashley Webb, \u2028Jeri-Carol Crumpton, James Lowe, Marie Gramer, and Richard J. Webby<\/p>\n<p>As a result of human-to-pig transmission, pandemic influenza A (H1N1) 2009 virus was detected in pigs soon after it emerged in humans. In the United States, this transmission was quickly followed by multiple reassortment between the pandemic virus and endemic swine viruses. Nine reassortant viruses representing 7 genotypes were detected in commercial pig farms in the United States. Field observations suggested that the newly described reassortant viruses did not differ substantially from pandemic (H1N1) 2009 or endemic strains in their ability to cause disease. Comparable growth properties of reassortant and endemic viruses in vitro supported these observations; similarly, a representative reassortant virus replicated in ferrets to the same extent as did pandemic (H1N1) 2009 and endemic swine virus. These novel reassortant viruses highlight the increasing complexity of influenza viruses within pig populations and the frequency at which viral diversification occurs in this ecologically important viral reservoir.<\/p>\n<p><strong>Download Article: <a href=\"https:\/\/streamllc.com\/newport\/wp-content\/uploads\/2022\/06\/3-NL-Multiple-Reassortant-SIV-3.pdf\" target=\"_blank\" rel=\"noopener\">Click here<\/a><\/strong><\/p>\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t<\/div><!-- .accordion-content -->\n\t    <\/li>\n\t\t    <li>\n\t\t\t<div class=\"accordion-title tf_rel\">\n\t\t\t\t<a href=\"#acc-6ydl266-3\" aria-controls=\"acc-6ydl266-3-content\" aria-expanded=\"false\">\n\t\t\t\t\t<i class=\"accordion-icon\"><svg  aria-hidden=\"true\" class=\"tf_fa tf-ti-plus\"><use href=\"#tf-ti-plus\"><\/use><\/svg><\/i>\t\t\t\t\t<i class=\"accordion-active-icon tf_hide\"><svg  aria-hidden=\"true\" class=\"tf_fa tf-ti-minus\"><use href=\"#tf-ti-minus\"><\/use><\/svg><\/i>\t\t\t\t\t<span class=\"tb_title_accordion tf_w\">Interlaboratory comparison of serologic assays for Porcine circovirus-2<\/span>\n\t\t\t\t<\/a>\n\t\t\t<\/div><!-- .accordion-title -->\n\n\t\t\t<div id=\"acc-6ydl266-3-content\" data-id=\"acc-6ydl266-3\" aria-hidden=\"true\" class=\"accordion-content tf_hide\">\n\n\t\t\t\t\t\t\t\t\t<div\t\t\t\t\t\tclass=\"tb_text_wrap\"\n\t\t\t\t\t\t>\n\t\t\t\t\t\t<p>Abby R. Patterson, John K. Johnson, Sheela Ramamoorthy, Richard A. Hesse,<br>Michael P. Murtaugh, Sumathy Puvanendiran, Roman M. Pogranichniy, Gene A. Erickson,<br>Susy Carman, Ben Hause, Xiang-Jin Meng, TanjaOpriessnig<\/p>\n<p><strong>Abstract<\/strong><\/p>\n<p>A blinded interlaboratory assessment of the diagnostic agreement and accuracy of serologic tests for routine detection of antibodies against Porcine circovirus-2 (PCV-2), including indirect fluorescent antibody tests (IFATs) and enzyme-linked immunosorbent assays (ELISAs) was conducted in 7 North American laboratories. Serum samples were collected weekly, on trial days 0, 7, 14, 21, 28, 35, 42, and 49, from the following groups of animals: 1) negative controls ( n 5 7), 2) PCV-2a ( n 5 8), 3) PCV-2b ( n 5 8), 4) PCV-1 ( n 5 8), 5) PCV-2 vaccine A ( n 5 8; Ingelvac H CircoFLEX TM ), 6) PCV-2 vaccine B ( n 5 8; Circumvent H PCV2), and 7) PCV-2 vaccine C ( n 5 8; Suvaxyn H PCV2 One Dose). Results from each laboratory were analyzed by kappa and receiver operating characteristic (ROC) analysis.&nbsp;<\/p><p>Kappa analysis indicated that, by trial day 49, IFATs had almost perfect agreement, in-house ELISAs had fair to almost perfect agreement, and commercially available anti\u2013PCV-2 immunoglobulin G ELISAs (I or S) had moderate to substantial agreement. From trial days 14\u201349, the area under the ROC curve for the 2 laboratories that offered IFATs, the 4 laboratories that offered in-house ELISAs, and the 3 laboratories that used commercially available ELISAs ranged from 0.94 to 1.00, 0.72 to 1.00, and 0.95 to 1.00, respectively. However, test sensitivities varied based on laboratory-specific cutoffs that were used to dichotomize test results.<\/p>\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t<\/div><!-- .accordion-content -->\n\t    <\/li>\n\t    <\/ul>\n\n<\/div><!-- \/module accordion -->\t        <\/div>\n\t    \t<\/div>\n\t\t    <\/div>\n\t    <!-- \/row_inner -->\n\t<\/div>\n\t<!-- \/module_row -->\n\t<\/div>\n<!--\/themify_builder_content-->","protected":false},"excerpt":{"rendered":"<p>Published Research About Our Custom Vaccines Custom Made Vaccines have been used for many years to help address livestock diseases. Newport Laboratories has applied 21st century technology to the traditional autogenous approach to produce high quality biologics for the livestock industry. These products are formulated and produced to pinpoint the specific disease problems in your [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":25,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"builder_content":"<h1>Published Research<\/h1>\n<h2 style=\"text-align: center;\">About Our Custom Vaccines<\/h2>\n<p>Custom Made Vaccines have been used for many years to help address livestock diseases. Newport Laboratories has applied 21st century technology to the traditional autogenous approach to produce high quality biologics for the livestock industry. These products are formulated and produced to pinpoint the specific disease problems in your livestock. Our dedicated employees, quality products, innovative solutions and personalized customer service, are the catalyst for Newport Laboratories' success. Today, we provide Custom Made Vaccines for customers across the country.<\/p> <p>We invite you to look through this section of our website, and contact us to discuss how Newport Laboratories can become your partner in improving and maintaining the health of your livestock. Custom Made Vaccines are sold exclusively through practicing veterinarians. For more information about Custom Made Vaccines, contact Newport Laboratories at 800-220-2522 or contact us.<\/p>\n<ul><li><h4>Antigenic catergorization of contemporary H3N2 Swine Influenza Virus isolates using a high-throughput serum neutralization assay<\/h4><p>Ben M. Hause,1 Tracy A. Oleson, Russell F. Bey,<br>Douglas L. Stine, Randy R. Simonson<\/p> <p><strong>Abstract<\/strong><\/p> <p>In vivo, neutralizing antibodies are critical for viral clearance. A high-throughput serum neutralization (HTSN) assay was developed to antigenically categorize Swine influenza virus (SIV) isolates. Uncategorized viruses were tested using a panel of antisera representing the H3N2 SIV subtypes and the results expressed as a serum neutralization ratio. Antisera were generated against contemporary isolates representing circulating H3N2 SIV subtypes (clusters I, III, IV). Reference viruses and the corresponding antisera were evaluated using traditional hemagglutination inhibition (HI) and the HTSN assays and good correlation (r 5 0.84) was observed between the 2 tests. Categorical clustering of 40 recent (2008\u20132009) SIV isolates was assessed using the HTSN assay. The H3N2 SIV isolates with amino acid similarity. 97% to the commonly used H3N2 cluster IV reference strain A\/Swine\/Ontario\/33853\/2005 (ON05) showed strong reactivity with cluster IV antisera. Isolates with, 97% amino acid similarity to ON05 sporadically or completely failed to react with any antiserum. A cluster of 3 isolates with weak reaction with cluster III antiserum may be a potential emerging cluster of H3N2 with moderate genetic similarity to cluster II H3N2 (93% similarity). Potential uses of the HTSN assay include identification of broadly cross-reactive or antigenically distinct SIV isolates for use in vaccine virus selection or as part of surveillance efforts monitoring antigenic drift.<\/p> <p><strong>Download Article: <a href=\"https:\/\/streamllc.com\/newport\/wp-content\/uploads\/2022\/06\/1-NL-Analysis-of-SIV-Serum-Neutralization-1_0.pdf\" target=\"_blank\" rel=\"noopener\">Click here<\/a><\/strong><\/p><\/li><li><h4>Genetic and antigenic characterization of recent human-like H1 (d-cluster) Swine Influenza Virus isolates<\/h4><p>Genetic and antigenic characterization of recent human-like H1 (d-cluster) Swine Influenza Virus isolates<br>Ben M. Hause, MS; Tracy A. Oleson, MS;\u2028Douglas L. Stine, DVM, PhD; Russell F. Bey,\u2028PhD; Randy R. Simonson, PhD<\/p> <p>To assess genetic and antigenic properties of contemporary human-like H1 (d-cluster) swine influenza virus (SIV) isolates circulating in US swine herds. (As published in the Journal of Swine Health &amp; Production)<\/p> <p><strong>Download Article: <a href=\"https:\/\/streamllc.com\/newport\/wp-content\/uploads\/2022\/06\/2-NL-Genetic-Antigenic-Characterization-of-H1-delta-cluster-SIV-2_0.pdf\" target=\"_blank\" rel=\"noopener\">Click here<\/a><\/strong><\/p><\/li><li><h4>Multiple Reassortment between Pandemic (H1N1) 2009 and Endemic Influenza Viruses in Pigs, United States<\/h4><p>Mariette F. Ducatez, Ben Hause, Evelyn Stigger-Rosser, Daniel Darnell, Cesar Corzo, Kevin Juleen, \u2028Randy Simonson, Christy Brockwell-Staats, Adam Rubrum, David Wang, Ashley Webb, \u2028Jeri-Carol Crumpton, James Lowe, Marie Gramer, and Richard J. Webby<\/p> <p>As a result of human-to-pig transmission, pandemic influenza A (H1N1) 2009 virus was detected in pigs soon after it emerged in humans. In the United States, this transmission was quickly followed by multiple reassortment between the pandemic virus and endemic swine viruses. Nine reassortant viruses representing 7 genotypes were detected in commercial pig farms in the United States. Field observations suggested that the newly described reassortant viruses did not differ substantially from pandemic (H1N1) 2009 or endemic strains in their ability to cause disease. Comparable growth properties of reassortant and endemic viruses in vitro supported these observations; similarly, a representative reassortant virus replicated in ferrets to the same extent as did pandemic (H1N1) 2009 and endemic swine virus. These novel reassortant viruses highlight the increasing complexity of influenza viruses within pig populations and the frequency at which viral diversification occurs in this ecologically important viral reservoir.<\/p> <p><strong>Download Article: <a href=\"https:\/\/streamllc.com\/newport\/wp-content\/uploads\/2022\/06\/3-NL-Multiple-Reassortant-SIV-3.pdf\" target=\"_blank\" rel=\"noopener\">Click here<\/a><\/strong><\/p><\/li><li><h4>Interlaboratory comparison of serologic assays for Porcine circovirus-2<\/h4><p>Abby R. Patterson, John K. Johnson, Sheela Ramamoorthy, Richard A. Hesse,<br>Michael P. Murtaugh, Sumathy Puvanendiran, Roman M. Pogranichniy, Gene A. Erickson,<br>Susy Carman, Ben Hause, Xiang-Jin Meng, TanjaOpriessnig<\/p> <p><strong>Abstract<\/strong><\/p> <p>A blinded interlaboratory assessment of the diagnostic agreement and accuracy of serologic tests for routine detection of antibodies against Porcine circovirus-2 (PCV-2), including indirect fluorescent antibody tests (IFATs) and enzyme-linked immunosorbent assays (ELISAs) was conducted in 7 North American laboratories. Serum samples were collected weekly, on trial days 0, 7, 14, 21, 28, 35, 42, and 49, from the following groups of animals: 1) negative controls ( n 5 7), 2) PCV-2a ( n 5 8), 3) PCV-2b ( n 5 8), 4) PCV-1 ( n 5 8), 5) PCV-2 vaccine A ( n 5 8; Ingelvac H CircoFLEX TM ), 6) PCV-2 vaccine B ( n 5 8; Circumvent H PCV2), and 7) PCV-2 vaccine C ( n 5 8; Suvaxyn H PCV2 One Dose). Results from each laboratory were analyzed by kappa and receiver operating characteristic (ROC) analysis.&nbsp;<\/p><p>Kappa analysis indicated that, by trial day 49, IFATs had almost perfect agreement, in-house ELISAs had fair to almost perfect agreement, and commercially available anti\u2013PCV-2 immunoglobulin G ELISAs (I or S) had moderate to substantial agreement. From trial days 14\u201349, the area under the ROC curve for the 2 laboratories that offered IFATs, the 4 laboratories that offered in-house ELISAs, and the 3 laboratories that used commercially available ELISAs ranged from 0.94 to 1.00, 0.72 to 1.00, and 0.95 to 1.00, respectively. However, test sensitivities varied based on laboratory-specific cutoffs that were used to dichotomize test results.<\/p><\/li><\/ul>","_links":{"self":[{"href":"https:\/\/staging.newportlabs.com\/index.php\/wp-json\/wp\/v2\/pages\/103"}],"collection":[{"href":"https:\/\/staging.newportlabs.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/staging.newportlabs.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/staging.newportlabs.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/staging.newportlabs.com\/index.php\/wp-json\/wp\/v2\/comments?post=103"}],"version-history":[{"count":3,"href":"https:\/\/staging.newportlabs.com\/index.php\/wp-json\/wp\/v2\/pages\/103\/revisions"}],"predecessor-version":[{"id":109,"href":"https:\/\/staging.newportlabs.com\/index.php\/wp-json\/wp\/v2\/pages\/103\/revisions\/109"}],"up":[{"embeddable":true,"href":"https:\/\/staging.newportlabs.com\/index.php\/wp-json\/wp\/v2\/pages\/25"}],"wp:attachment":[{"href":"https:\/\/staging.newportlabs.com\/index.php\/wp-json\/wp\/v2\/media?parent=103"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}